Skip to main content
Clinical Trials/CTRI/2020/09/027770
CTRI/2020/09/027770
Active, not recruiting
未知

The use of physiologic assessment and functional SYNTAX score in influencing the treatment strategy for Multi-Vessel Disease (MVD) patients involving intermediate decisions compared to conventional angiography and anatomical SYNTAX score in a real-world scenario

Dr Nattawut Wongpraparut from Faculty of Medicine Siriraj Hospital0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: I248- Other forms of acute ischemic heart disease
Sponsor
Dr Nattawut Wongpraparut from Faculty of Medicine Siriraj Hospital
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Dr Nattawut Wongpraparut from Faculty of Medicine Siriraj Hospital

Eligibility Criteria

Inclusion Criteria

  • 1\. Age \>18 years
  • 2\. Willing to participate and able to understand, read and sign the informed consent document before the planned procedure
  • 3\. Eligible for coronary angiography and/or percutaneous coronary intervention
  • 4\. Stable angina
  • 5\. Recent and stabilized NSTEMI
  • Angiographic inclusion criteria
  • \- Coronary artery disease in two or more native major epicardial vessels or their branches by coronary angiogram with visually assessed de novo coronary stenosis in which one of the lesion has the physiological severity of the lesion is in question (typically 50\-90% diameter stenosis)
  • \- All lesions are amenable to revascularizationÂ

Exclusion Criteria

  • \- Terminal disease with life expectancy of less than 12 months
  • \- Any patient who at the time of planned angiography has ongoing ischemic symptoms
  • \- Angiography performed in the context of primary PCI of STEMI
  • \- Acute coronary syndrome with difficulty in assessing the culprit lesion
  • \- Pregnancy
  • \- Severe aortic stenosis
  • \- Significant valvular heart disease indicated for concomitant valve surgery
  • \- Cardiogenic shock or hemodynamic instability
  • \- Contraindication to adenosine
  • \- Previous CABG

Outcomes

Primary Outcomes

Not specified

Similar Trials